Физиологическая роль и клинические эффекты мелатонина
- Авторы: Леваков С.1, Боровкова Е.1
-
Учреждения:
- Первый МГМУ им. И.М. Сеченова
- Выпуск: Том 26, № 3 (2015)
- Страницы: 72-75
- Раздел: Статьи
- URL: https://journals.eco-vector.com/0236-3054/article/view/116321
- ID: 116321
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Мелатонин обладает широким спектром активности, но основная его функция - нормализация сна. Приводятся данные клинических исследований, позволяющие расширить показания к применению препаратов мелатонина.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
С. Леваков
Первый МГМУ им. И.М. Сеченова
Е. Боровкова
Первый МГМУ им. И.М. Сеченова
Email: katyanikitina@mail.ru
Список литературы
- Ariens-Kappers J. Innervation of the Epiphysis cerebri in the albino rat // Anat. Rec. - 1960; 136: 220.
- Axelrod J., Shein H., Wurtman R. Stimulation of C14-melatonin synthesis from C14-tryptophan by noradrenaline in rat pineal in organ culture // Proc. Natl. Acad. Sci. USA. - 1969; 62: 544.
- Anisimov V., Alimova I., Baturin D. et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice // Exp. Gerontol. - 2003; 38: 449.
- Aoki H., Yamada N., Ozeki Y. et al. Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva // Neurosci. Lett. -1998; 252: 91.
- Atkinson G., Jones H., Edwards B. et al. Effects of daytime ingestion of melatonin on short-term athletic performance // Ergonomics. - 2005; 48: 1512.
- Bonn, D. Melatonin's multifarious marvels: Miracle or myth? // Lancet. -1996; 347: 184.
- Brzezinski A. Melatonin in humans // N. Engl. J. Med. - 1997; 336: 186.
- Brzezinski A., Vangel M., Wurtman R. et al. Effects of exogenous melatonin on sleep: a meta-analysis // Sleep Med. Rev. - 2005; 9: 41.
- Buscemi N., Vandermeer B., Pandya R. et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/melatsum.htm (Accessed on September 23, 2011).
- Buscemi N., Vandermeer B., Hooton N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis // J. Gen. Intern. Med. - 2005; 20: 1151.
- Cagnacci A., Cannoletta M., Renzi A. et al. Prolonged melatonin administration decreases nocturnal blood pressure in women // Am. J. Hypertens. - 2005; 18: 1614.
- Duell P., Wheaton D., Shultz A. et al. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations // Clin. Chem. - 1998; 44: 1931-36.
- Ekman A., Leppäluoto J., Huttunen P. et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study // J. Clin. Endocrinol. Metab. - 1993; 77: 780.
- Erman M., Seiden D., Zammit G. et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia // Sleep Med. - 2006; 7: 17.
- Fiske V., Bryant K., Putnam J. Effect of light on the weight of pineal in the rat // J. Endocrinol. - 1960; 66: 489.
- Grossman E., Laudon M., Yalcin R. et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension // Am. J. Med. - 2006; 119: 898.
- Gerdin M., Masana M., Rivera-Bermúdez M. et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin // FASEB J. - 2004; 18: 1646.
- Gerdin M., Masana M., Dubocovich M.L. Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells // Biochem. Pharmacol. - 2004; 67: 2023-30.
- Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders // Curr. Opin. Investig. Drugs. -2009; 10: 691.
- Jonas M., Garfinkel D., Zisapel N. et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients // Blood Press. - 2003; 12: 19.
- Kitay J., Altschule M. Effects of pineal extract administration on ovary weight in rats // Endocrinol. - 1954; 55: 782.
- Klein D. The pineal gland: A model of neuroendocrine regulation. In: The Hypothalamus, Reichlin S., Baldessarini R., Martin J. (Eds) / New York: Raven Press, 1978; p. 303.
- Kopin I., Pare C., Axelrod J., et al. 6-Hydroxylation, the major metabolic pathway for melatonin // Biochim. Biophys. Acta. - 1960; 40: 377.
- Kennaway D., Stamp G., Goble F. Development of melatonin production in infants and the impact of prematurity // J. Clin. Endocrinol. Metab. - 1992; 75: 367.
- Lewy A., Wehr T., Goodwin F. et al. Lights up presses melatonin secretion in humans // Science. - 1980; 210: 1267.
- Lerner A., Case J., Takahashi Y. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am. Chem. Soc. - 1958; 80: 2587.
- Lynch H. Diurnal oscillations in pineal melatonin content // Life Sci. - 1971; 10: 791.
- Lynch H., Wurtman R., Moskowitz M. et al. Daily rhythm in human urinary melatonin // Science. - 1975; 187: 169.
- Lynch H., Jimerson D., Ozaki Y. et al. Entrainment of rhythmic melatonin secretion in man to a 12-hour phase shift in the light/dark cycle // Life Sci. - 1978; 23: 1557.
- Moore R., Klein D. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity // Brain Res. -1974; 71: 17.
- Pappolla M., Bozner P., Soto C. et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin // J. Biol. Chem. - 1998; 273: 7185.
- Pappolla M., Chyan Y., Poeggeler B. et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease // J. Neural. Transm. - 2000; 107: 203.
- Rodriguez C., Mayo J., Sainz R. et al. Regulation of antioxidant enzymes: a significant role for melatonin // J. Pineal. Res. - 2004; 36: 1.
- Röjdmark S., Wikner J., Adner N. et al. Inhibition of melatonin secretion by ethanol in man // Metabolism. - 1993; 42: 1047.
- Tricoire H., Locatelli A., Chemineau P. et al. Melatonin enters the cerebrospinal fluid through the pineal recess // Endocrinology. - 2002; 143: 84.
- Waldhauser F., Lynch H., Wurtman R. Melatonin in human body fluids: Clinical significance. In: The Pineal Gland (Comprehensive Endocrinology), Reiter R. (Ed) / New York: Raven Press, 1984; p. 345.
- Waldhauser F., Lieberman H., Lynch H. et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol // Neuroendocrinology. - 1987; 46: 125.
- Wang L., Suthana N., Chaudhury D. et al. Melatonin inhibits hippocampal long-term potentiation // Eur. J. Neurosci. - 2005; 22: 2231.
Дополнительные файлы
![](/img/style/loading.gif)